

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wei et al.
U.S. Serial No. : 10/650,365
Confirmation No.: 7677
Filed : August 28, 2003
Art Unit : 1646
Examiner Name : Bruce D. Hissong
For : RECOMBINANT SUPER-COMPOUND INTERFERON
Law Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357
September 24, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants would like to direct the Examiner's attention to the following references which are listed on Forms PTO/SB/08A and PTO/SB/08B (which are attached hereto as **Exhibit B**), and individual references further attached as **Exhibits 1-28**.

Applicants would like to note that listed reference 1 is a U.S. Patent. This document is on file at the USPTO. Accordingly, pursuant to 37 CFR 1.98(d), a copy of this reference is not required to be submitted with this SIDS.

Applicants' attorney's office may be contacted in the event that the Examiner would like a copy of the above references.

Applicants : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 2

References 7, 10, 11, 13, and 14 were brought to the Applicants' attention in office actions for related application U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US). Reference 6 was brought to the Applicants' attention in an office action for related application U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US).

1. U.S. Patent No. 6,114,145, OLSEN et al., September 5, 2000, "Synferon, a synthetic interferon."
2. International Publication WO 2005/034853 A2 for HUIYANGTECH (INC.) USA, Published April 21, 2005. PCT/US2004/028067, "Uses of interferons with altered spatial structure." [Exhibit 1]
3. Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2005. [Exhibit 2]
4. International Search Report for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2005. [Exhibit 3]
5. Australian Patent Number AU 2003248419 for WEI et al., November 6, 2003. "Recombinant super-compound interferon." [Exhibit 4]
6. Chinese Patent Number CN 1375502A for YAO et al., October 23, 2002. "Polyglycol modified recombinant human interferon." [Exhibit 5]

Applicants : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 3

7. Chinese Patent Number CN 1478545A for GAO et al., March 3, 2004. "Use of compound interferon in the treating of SARS disease." [Exhibit 6]
8. Ivan AMATO, January 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40. [Exhibit 7]
9. AUSUBEL et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8. [Exhibit 8]
10. CINATL et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294. [Exhibit 9]
11. DAY et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143. [Exhibit 10]
12. DUAN et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208. [Exhibit 11]
13. HIGGINS et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715. [Exhibit 12]
14. HOLLAND, C.C. and T.L. WRIGHT, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1). [Exhibit 13]

Applicants : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 4

15. NACKLEY, A.G. et al., December 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932. [Exhibit 14]
16. NASOFF et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11. [Exhibit 15]
17. PYRC, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders - Drug Targets, 7:59-66. [Exhibit 16]
18. ZHAO, Z. et al., 2003, "Description and clinical treatment of an early outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720. [Exhibit 17]
19. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated April 3, 2007. [Exhibit 18]
20. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated June 14, 2007. [Exhibit 19]
21. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated December 15, 2006. [Exhibit 20]
22. Advisory Action Before the Filing of an Appeal Brief for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated May 22, 2007. [Exhibit 21]

Applicants : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 5

23. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 9, 2007. [Exhibit 22]
24. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated February 9, 2007. [Exhibit 23]
25. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 22, 2006. [Exhibit 24]
26. U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 1, 2007. [Exhibit 25]
27. U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated November 27, 2006. [Exhibit 26]
28. U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 8, 2006. [Exhibit 27]
29. U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated September 19, 2007. [Exhibit 28]

Applicants : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 6

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan
Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
E-mail: chank@kitchanlaw.com